title: New Insights on Different Response of MDMA-Elicited Serotonin Syndrome to Systemic and Intracranial Administrations in the Rat Brain.
abstract: In spite of the fact that systemic administration of MDMA elicits serotonin syndrome, direct intracranial administration fails to reproduce the effect. To reconcile these findings, it has been suggested that the cause of serotonin syndrome is attributed mainly to MDMA hepatic metabolites, and less likely to MDMA itself. Recently, however, this explanation has been challenged, and alternative hypotheses need to be explored. Here, we tested the hypothesis that serotonin syndrome is the result of excessive 5HT simultaneously in many brain areas, while MDMA administered intracranially fails to cause serotonin syndrome because it produces only a localized effect at the delivery site and not to other parts of the brain. This hypothesis was examined using adult male Sprague Dawley rats by comparing 5HT responses in the right and left hemispheric frontal cortices, right and left hemispheric diencephalons, and medullar raphe nucleus. Occurrence of serotonin syndrome was confirmed by measuring change in body temperature. Administration routes included intraperitoneal (IP), intracerebroventricular (ICV) and reverse microdialysis. First, we found that IP administration caused excessive 5HT in all five sites investigated and induced hypothermia, suggesting the development of the serotonin syndrome. In contrast, ICV and reverse microdialysis caused excessive 5HT only in regions of delivery sites without changes in body-core temperature, suggesting the absence of the syndrome. Next, chemical dyes were used to trace differences in distribution and diffusion patterns between administration routes. After systemic administration, the dyes were found to be evenly distributed in the brain. However, the dyes administered through ICV or reverse microdialysis injection still remained in the delivery sites, poorly diffusing to the brain. In conclusion, intracranial MDMA administration in one area has no or little effect on other areas, which must be considered a plausible reason for the difference in MDMA-elicited serotonin syndrome between systemic and intracranial administrations.
authors.affiliation: Ross University School of Veterinary Medicine, St. Kitts, West Indies.|Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, United States of America.
authors.forename: Ibrahim M
authors.initials: IM
authors.lastname: Shokry
authors.affiliation: Ross University School of Veterinary Medicine, St. Kitts, West Indies.
authors.forename: John J
authors.initials: JJ
authors.lastname: Callanan
authors.affiliation: Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, United States of America.
authors.forename: John
authors.initials: J
authors.lastname: Sousa
authors.affiliation: Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, United States of America.
authors.forename: Rui
authors.initials: R
authors.lastname: Tao
mesh_terms: D000818:Animals; D001831:Body Temperature; D001921:Brain / Q000187:drug effects* / Q000378:metabolism*; D004333:Drug Administration Routes; D008297:Male; D017551:Microdialysis; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000008:administration & dosage* / Q000633:toxicity*; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D020230:Serotonin Syndrome / Q000209:etiology* / Q000378:metabolism*
chemical_list: D012701:Serotonin; D018817:N-Methyl-3,4-methylenedioxyamphetamine